332 related articles for article (PubMed ID: 32167790)
1. Evolution of the inclusion/exclusion criteria and primary endpoints in pivotal trials of biologics and small oral molecules for the treatment of psoriasis.
Hsu SH; Tsai TF
Expert Rev Clin Pharmacol; 2020 Mar; 13(3):211-232. PubMed ID: 32167790
[No Abstract] [Full Text] [Related]
2. Biologics in pediatric psoriasis - efficacy and safety.
Dogra S; Mahajan R
Expert Opin Drug Saf; 2018 Jan; 17(1):9-16. PubMed ID: 29022425
[TBL] [Abstract][Full Text] [Related]
3. Biologics in the treatment of pustular psoriasis.
Wang WM; Jin HZ
Expert Opin Drug Saf; 2020 Aug; 19(8):969-980. PubMed ID: 32615817
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.
Armstrong AW; Puig L; Joshi A; Skup M; Williams D; Li J; Betts KA; Augustin M
JAMA Dermatol; 2020 Mar; 156(3):258-269. PubMed ID: 32022825
[TBL] [Abstract][Full Text] [Related]
5. A safety review of recent advancements in the treatment of psoriasis: analysis of clinical trial safety data.
Kolli SS; Kepley AL; Cline A; Feldman SR
Expert Opin Drug Saf; 2019 Jun; 18(6):523-536. PubMed ID: 31046481
[TBL] [Abstract][Full Text] [Related]
6. A drug safety evaluation of risankizumab for psoriasis.
Huang YW; Tsai TF
Expert Opin Drug Saf; 2020 Apr; 19(4):395-402. PubMed ID: 32100591
[No Abstract] [Full Text] [Related]
7. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
[TBL] [Abstract][Full Text] [Related]
8. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
Weinberg JM
Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
[TBL] [Abstract][Full Text] [Related]
9. Switching biologics in psoriasis - practical guidance and evidence to support.
Tsai YC; Tsai TF
Expert Rev Clin Pharmacol; 2020 May; 13(5):493-503. PubMed ID: 32394765
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
[TBL] [Abstract][Full Text] [Related]
11. The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis.
D'Adamio S; Silvaggio D; Lombardo P; Bianchi L; Talamonti M; Galluzzo M
Expert Opin Drug Saf; 2019 Nov; 18(11):1031-1041. PubMed ID: 31479282
[No Abstract] [Full Text] [Related]
12. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
Sawyer LM; Cornic L; Levin LÅ; Gibbons C; Møller AH; Jemec GB
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):355-366. PubMed ID: 30289198
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue.
Takamura S; Sugai S; Taguchi R; Teraki Y
J Dermatol; 2020 Mar; 47(3):290-294. PubMed ID: 31867729
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
Reich K; Burden AD; Eaton JN; Hawkins NS
Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
[TBL] [Abstract][Full Text] [Related]
15. Safety of biologics in psoriasis.
Kamata M; Tada Y
J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
[TBL] [Abstract][Full Text] [Related]
16. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
Warren RB; Gooderham M; Burge R; Zhu B; Amato D; Liu KH; Shrom D; Guo J; Brnabic A; Blauvelt A
J Am Acad Dermatol; 2020 May; 82(5):1138-1149. PubMed ID: 31884091
[TBL] [Abstract][Full Text] [Related]
17. Guselkumab for the treatment of moderate-to-severe plaque psoriasis.
Yang EJ; Sanchez IM; Beck K; Sekhon S; Wu JJ; Bhutani T
Expert Rev Clin Pharmacol; 2018 Apr; 11(4):333-344. PubMed ID: 29478344
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of biologics in psoriasis: a review.
Kim IH; West CE; Kwatra SG; Feldman SR; O'Neill JL
Am J Clin Dermatol; 2012 Dec; 13(6):365-74. PubMed ID: 22967166
[TBL] [Abstract][Full Text] [Related]
19. Biologic agents in the treatment of psoriasis.
Guarneri F; Guarneri C; Guarneri B
Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):193-217. PubMed ID: 19075983
[TBL] [Abstract][Full Text] [Related]
20. Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review.
Reynolds KA; Pithadia DJ; Lee EB; Han G; Wu JJ
Expert Opin Drug Saf; 2020 Apr; 19(4):459-466. PubMed ID: 32116071
[No Abstract] [Full Text] [Related]
[Next] [New Search]
